Which companies are poised to dominate the diabetes market?  With new classes on the rise, which innovative therapies will make an impact?  How will clinical results and safety issues affect drug profitability over the long term?

CEI’s veteran analysts answer these questions — and more — by placing critical drug information in a relevant industry-wide context.  Other reports skim the surface, examining only top drugs at top companies.  Ours is complete, covering marketed brands, pipeline products, clinical development, whole drug classes and top drug manufacturers — all in one, easy-to-read format.

From showing the most accurate sales projections and pipelines to identifying market threats and opportunities, “Diabetes Market Forecast to 2013” provides teams with a hard-hitting, penetrating analysis of the global diabetes market. For reliable evidence to support key resource allocation decisions, this is the only resource you’ll need.

Give your brand team all the diabetes data it needs to make critical product decisions!

 

More Cutting Edge Information Reports: